Long COVID: A Primer for Family Physicians

Trisha Greenhalgh, BM BChir, MD, PhD, MBA
University of Oxford, Oxford, United Kingdom
Matthew Knight, MBBS, BSc, PGCert (Allergy) FRCP, West Hertfordshire Hospitals National Health Services Trust, Watford, United Kingdom


Published online November 18, 2020.

As the United States struggles with a prolonged wave of acute coronavirus disease 2019 (COVID-19; see article recently published in American Family Physician), family physicians need to be prepared to care for patients presenting with postacute (one to three months) or chronic (beyond three months) manifestations of this complex disease.

Among nonhospitalized patients with COVID-19, two-thirds are symptom-free by 14 days after symptom onset, and 90% are symptom-free by 21 days. The rest of patients experience persistent—or relapsing and remitting—symptoms, including cough, breathlessness, fatigue, fever, sore throat, nonspecific chest pains (lung burn), cognitive blunting (brain fog), anxiety, depression, skin rashes, and diarrhea.

The term long COVID was coined by online communities of patients who felt dismissed by their physicians as overreacting to “mild” illness. However, evidence is accumulating that long COVID is a distinct syndrome, perhaps due to a dysfunctional immune-inflammatory response, that can affect people who were never hospitalized and may occur without a history of a polymerase chain reaction test positive for COVID-19. There are no official guidelines for the management of long COVID, but a recent review has highlighted some important principles, which we will briefly summarize.

The key task of the family physician is to distinguish patients with life-threatening or serious post-COVID complications from those with less concerning symptoms. Serious complications include pulmonary embolus, heart failure, stroke, myocardial infarction, lung fibrosis, neurologic derangement, and severe deterioration in mental health. Patients presenting with nonserious symptoms benefit from support and reassurance through a natural process of convalescence.

Evaluation for alternative diagnoses (e.g., deteriorating comorbidities, infection, endocrine disturbance) is vital because not all illness in a patient recovering from COVID-19 is caused by postacute COVID-19.

Detailing the history of the acute disease, including biometric readings (e.g., oxygen saturations), and the subsequent clinical course is essential. Current symptoms should be noted and prioritized. Red flag symptoms, such as chest pain, should be carefully explored. Medications, including over-the-counter and alternative therapies, should be checked. A social history may reveal relevant issues, such as isolation, economic hardship, pressure to return to work, bereavement, or loss of personal routines (e.g., shopping, church), which can impact patients’ well-being.

Although remote assessment may be appropriate, in some cases, a physiologic evaluation of patients with prolonged symptoms should be combined with a review of functional status and mental well-being. Patients with oxygen saturation persistently below 95% require additional evaluation. In patients whose oxygen saturation is 96% or above at rest, tests for exertional desaturation (e.g., 40 steps around the room and, if negative, followed by a one-minute sit-stand assessment supervised by a health care professional) may be informative. If the exertional test results in a drop of 3% or more in oxygen saturation, further assessment is warranted. Home self-monitoring of oxygen saturation using a patient diary may provide further reassurance.

Blood tests and imaging should be guided by the clinical assessment. When indicated, tests may include complete blood count; liver and kidney function; urinalysis; d-dimer assay; and measurements of electrolytes, C-reactive protein, troponin, ferritin (useful in evaluating inflammatory and prothrombotic states), and brain natriuretic peptides. In those with cardiac symptoms, a 12-lead electrocardiograph can be reassuring if findings are normal, but abnormal findings, combined with concerning clinical and blood test findings, should prompt further cardiac investigation.

Patients with acute COVID-19 and abnormal findings on chest imaging or significant respiratory illness should have repeat chest radiography at 12 weeks or earlier. Repeat chest imaging may not be needed otherwise if cough and breathlessness...
References


